Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma



Status:Recruiting
Conditions:Asthma
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:5 - 17
Updated:10/7/2018
Start Date:October 20, 2017
End Date:October 31, 2020
Contact:US GSK Clinical Trials Call Center
Email:GSKClinicalSupportHD@gsk.com
Phone:877-379-3718

Use our guide to learn which trials are right for you!

A Randomised, Double-blind, Parallel Group, Multicentre, Stratified, Study Evaluating the Efficacy and Safety of Once Daily Fluticasone Furoate/Vilanterol Inhalation Powder Compared to Once Daily Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Participants Aged 5 to 17 Years Old (Inclusive) Currently Uncontrolled on Inhaled Corticosteroids

The goal of asthma treatment is to achieve and maintain asthma control and to reduce the
future risk of exacerbations. Inhaled corticosteroids (ICS) are considered as the most
effective anti- inflammatory treatment for all severities of persistent asthma. For children
>=5 years of age and adolescents whose asthma is uncontrolled, low-dose ICS plus adjunctive
therapy with long-acting beta agonist (LABA) is considered as effective. Thus, this study is
designed to evaluate the efficacy and safety of FF (ICS component)/VI (LABA component)
compared to FF alone for the treatment of asthma, in subjects aged 5 to 17 years old
currently uncontrolled on ICS. The study will be conducted over a total duration of
approximately 29 weeks: 4 week run-in period, 24-week double-blind treatment period and
1-week follow-up period. Subjects will be randomized to receive FDC of FF/VI or FF
administered via ELLIPTA® dry powder inhaler (DPI). The dose of both FF/VI and FF alone will
be selected based on the age of subjects. Subjects will receive a short acting beta 2 agonist
(SABA) (albuterol /salbutamol) as a rescue medication throughout the study. A total of 870
subjects will be randomized in the study. Of this, 652 subjects will be aged 5 to 11 years
(cohort A), and 218 will be aged 12 to 17 years inclusive (cohort B). ELLIPTA is a registered
trademark of GlaxoSmithKline (GSK) group of companies.


Inclusion Criteria:

- For all subjects: Between 5 and 17 years of age inclusive, at the time of signing the
informed consent.

- A history of symptoms consistent with a diagnosis of asthma for at least 6 months.

- Pre-bronchodilator FEV1 >50 percent to <=90 percent predicted normal. A minimum of 2
efforts that are considered acceptable (not necessarily repeatable) are required to be
eligible.

- Lung function reversibility defined as an increase of >=12 percent in FEV1 within 10
to 40 minutes following 2 to 4 inhalations of salbutamol inhalation aerosol (or 1
nebulized treatment with albuterol/salbutamol solution). Use of a spacer is permitted.

- Uncontrolled asthma, with a childhood asthma control test (cACT)/ACT score <=19.

- Receiving stable asthma therapy (SABA inhaler plus ICS [total daily dose <=FP 250
micrograms (mcg) or equivalent]) for at least 4 weeks prior to Visit 1 (i.e.
screening).

- Able to replace their current SABA treatment with salbutamol aerosol inhaler at Visit
1 for use as needed for the duration of the study. Salbutamol metered dose inhaler
(MDI) will be administered with or without a spacer, to be used as determined by the
investigator. The use or non-use of the spacer should be consistent for an individual
subject throughout the study.

- Male or female subjects will be included. Females of reproductive potential must agree
to follow 1 of the options listed (which include abstinence) in the Modified List of
Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential
(FRP) from 30 days prior to the first dose of study medication and until at least five
terminal half-lives or until any continuing pharmacologic effect has ended, whichever
is longer after the last dose of study medication and completion of the follow-up
call. The investigator is responsible for ensuring that subjects understand how to
properly use these methods of contraception.

- Written informed consent from at least 1 parent/care giver (legal guardian) and
accompanying informed assent from the subject (where the subject is able to provide
assent) prior to admission to the study. If applicable, subject must be able and
willing to give assent to take part in the study according to the local requirement.
The study investigator is accountable for determining a child's capacity to assent to
participation in a research study, taking into consideration any standards set by the
responsible independent ethics committee (IEC); subject and their legal guardian(s)
understand that the study requires them to be treated on an outpatient basis; subject
and their legal guardian(s) understand that they must comply with study medication and
study assessments including recording of PEF and rescue SABA use, attending scheduled
study visits, and being accessible by a telephone call.

- For subjects eligible for randomization; asthma control: uncontrolled asthma, with a
cACT/ACT score <=19.

- A technically acceptable pre-bronchodilator FEV1 >50 percent to <=90 percent predicted
normal at Visit 2. A minimum of 2 efforts that are considered acceptable and
repeatable following the over read are required to be eligible.

- Symptoms and rescue use: demonstrated and reported in a daily diary symptoms of asthma
(a score of >=1 on the day-time or night-time asthma symptom scores) and/or daily
albuterol/salbutamol on at least 3 of the last 7 consecutive days of the run-in period
(not including the date of randomization).

- Compliance with run-in medication: compliance is defined as use of run-in medication
on at least 4 of the last 7 consecutive days of the run-in period (not including the
date of randomization) recorded in the electronic subject diary.

- Compliance with completion of the daily diary reporting: defined as completion of all
questions on 4 out of the last 7 days during the run-in period (not including the date
of randomization).

Exclusion Criteria:

- For all subjects: History of life threatening asthma defined as an asthma episode that
required intubation and/or was associated with hypercapnea, respiratory arrest or
hypoxic seizures.

- Any asthma exacerbation requiring the use of oral steroids within 6 weeks of Visit 1,
systemic or depot corticosteroids within 12 weeks of Visit 1, or ER attendance within
3 months of Visit 1 or hospitalization within 6 months of Visit 1.

- A culture documented or suspected bacterial or viral infection of the upper or lower
respiratory tract, sinus or middle ear that has not resolved within 4 weeks of Visit 1
and which led to a change in asthma management or, in the opinion of the investigator,
is expected to affect the subject's asthma status or the subject's ability to
participate in the study.

- Clinical visual evidence of oropharyngeal candidiasis.

- Fasting blood glucose at screening >100 milligrams/deciliter (mg/dL) (5.6 moles per
liter [mol/L]).

- Obesity (Body Mass Index [BMI] above the 97th centile based on the centers for disease
control and prevention [CDC] charts).

- Any significant abnormality or medical condition identified at the screening medical
assessment (including serious psychological disorder) that in the investigator's
opinion, preclude entry into the study due to risk to the subject or that may
interfere with the conduct and/or outcome of the study.

- QTc >450 milliseconds (msec) or QTc >480 msec in subjects with bundle branch block or
any other clinically significant abnormality in the screening 12-lead ECG.

- Use of any prohibited medications.

- Present use of any tobacco products.

- Drug allergies: any adverse reaction including immediate or delayed hypersensitivity
to any beta 2-agonists, sympathomimetic drug or any intranasal, inhaled, or systemic
corticosteroid therapy. Known or suspected sensitivity to the constituents of the
ELLIPTA Inhaler (i.e. lactose or magnesium stearate).

- Milk Protein Allergy: history of severe milk protein allergy.

- Participated in a clinical trial and has received an investigational product within
the following time period prior to the first dosing day in the current study: 30 days,
five half-lives or twice the duration of the biological effect of the study treatment
(whichever is longer).

- Exposure to more than 4 investigational medicinal products within 12 months prior to
the first dosing day.

- An affiliation with the investigator site: the parents/guardians or child is an
immediate family member of the participating investigator, sub-investigator, study
coordinator, or employee of the participating investigator.

- The parent or guardian has a history of psychiatric disease, intellectual deficiency,
substance abuse or other condition (example, inability to read, comprehend or write)
which may affect: validity of consent to participate in the study; adequate
supervision of the subject during the study; compliance of subject with study
medication and study procedures (example, completion of daily diary, attending
scheduled clinic visits); subject safety and well-being.

- Children in care: children who are wards of the government or state are not eligible
for participation in this study.

- For subjects eligible for randomization; Changes in asthma medication that occur after
screening.

- Occurrence of a culture-documented or suspected bacterial or viral infection of the
upper or lower respiratory tract, sinus or middle ear during the run-in period that
led to a change in asthma management or, in the opinion of the investigator, is
expected to affect the subject's asthma status or the subject's ability to participate
in the study.

- Evidence of an exacerbation, defined as a: deterioration of asthma requiring the use
of oral corticosteroids for at least 3 days, or a depot corticosteroid injection, or
an in-patient hospitalization due to asthma that required systemic corticosteroids
between screening and randomization.

- Clinical visual evidence of oropharyngeal candidiasis at the randomization Visit.

- Unable to use the ELLIPTA inhaler correctly.
We found this trial at
37
sites
Raleigh, North Carolina 27614
Phone: 877-379-3718
?
mi
from
Raleigh, NC
Click here to add this to my saved trials
Asheville, North Carolina 28803
Phone: 877-379-3718
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Baltimore, Maryland 21201
Phone: 877-379-3718
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Belleville, New Jersey 07109
Phone: 877-379-3718
?
mi
from
Belleville, NJ
Click here to add this to my saved trials
Brick, New Jersey 08723
Phone: 877-379-3718
?
mi
from
Brick, NJ
Click here to add this to my saved trials
Charlotte, North Carolina 28203
Phone: 877-379-3718
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Ciudad Autonoma de Buenos Aires, Buenos Aires
Phone: 877-379-3718
?
mi
from
Ciudad Autonoma de Buenos Aires,
Click here to add this to my saved trials
Denver, Colorado 80206
Phone: 877-379-3718
?
mi
from
Denver, CO
Click here to add this to my saved trials
Des Moines, Iowa 50314
Phone: 877-379-3718
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
Edison, New Jersey
Phone: 877-379-3718
?
mi
from
Edison, NJ
Click here to add this to my saved trials
Evanston, Illinois 60201
Phone: 877-379-3718
?
mi
from
Evanston, IL
Click here to add this to my saved trials
Evansville, Indiana 47714
Phone: 877-379-3718
?
mi
from
Evansville, IN
Click here to add this to my saved trials
Gainesville, Georgia 30501
Phone: 877-379-3718
?
mi
from
Gainesville, GA
Click here to add this to my saved trials
Great Neck, New York 11023
Phone: 877-379-3718
?
mi
from
Great Neck, NY
Click here to add this to my saved trials
Grove City, Ohio 43123
Phone: 877-379-3718
?
mi
from
Grove City, OH
Click here to add this to my saved trials
Hialeah, Florida 33013
Phone: 877-379-3718
?
mi
from
Hialeah, FL
Click here to add this to my saved trials
Homestead, Florida 33030
Phone: 877-379-3718
?
mi
from
Homestead, FL
Click here to add this to my saved trials
Hoover, Alabama 35216
Phone: 877-379-3718
?
mi
from
Hoover, AL
Click here to add this to my saved trials
Houston, Texas 77030
Phone: 877-379-3718
?
mi
from
Houston, TX
Click here to add this to my saved trials
Huntington Beach, California 92647
Phone: 877-379-3718
?
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Lewisville, Texas 75067
Phone: 877-379-3718
?
mi
from
Lewisville, TX
Click here to add this to my saved trials
Little Rock, Arkansas 72205
Phone: 877-379-3718
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Madison, Wisconsin 53792
Phone: 877-379-3718
?
mi
from
Madison, WI
Click here to add this to my saved trials
Medford, Oregon 97504
Phone: 877-379-3718
?
mi
from
Medford, OR
Click here to add this to my saved trials
Miami, Florida 33136
Phone: 877-379-3718
?
mi
from
Miami, FL
Click here to add this to my saved trials
Miami Lakes, Florida 33014
Phone: 877-379-3718
?
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
Ocala, Florida 34471
Phone: 877-379-3718
?
mi
from
Ocala, FL
Click here to add this to my saved trials
Orangeburg, South Carolina 29118
Phone: 877-379-3718
?
mi
from
Orangeburg, SC
Click here to add this to my saved trials
Owensboro, Kentucky 42303
Phone: 877-379-3718
?
mi
from
Owensboro, KY
Click here to add this to my saved trials
Piscataway, New Jersey 08854
Phone: 877-379-3718
?
mi
from
Piscataway, NJ
Click here to add this to my saved trials
Riverside, California 92506
Phone: 877-379-3718
?
mi
from
Riverside, CA
Click here to add this to my saved trials
San Antonio, Texas 78258
Phone: 877-379-3718
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Spartanburg, South Carolina 29303
Phone: 877-379-3718
?
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Summerville, South Carolina 29485
Phone: 877-379-3718
?
mi
from
Summerville, SC
Click here to add this to my saved trials
Waco, Texas 76712
Phone: 877-379-3718
?
mi
from
Waco, TX
Click here to add this to my saved trials
Wexford, Pennsylvania 15090
Phone: 877-379-3718
?
mi
from
Wexford, PA
Click here to add this to my saved trials
Ypsilanti, Michigan 48197
Phone: 877-379-3718
?
mi
from
Ypsilanti, MI
Click here to add this to my saved trials